v3.26.1
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
The following tables represent revenues by geographic region and reportable segment for the three and six months ended June 30, 2026 and 2025. Results for the three and six months ended June 30, 2025 reflect the recast of segment information based on the changes described in Note 14.
Three Months Ended June 30, 2026
(in millions)Commercial SolutionsResearch & Development SolutionsTotal
Revenues:
Americas$895 $1,144 $2,039 
Europe and Africa687 722 1,409 
Asia-Pacific211 709 920 
Total revenues$1,793 $2,575 $4,368 
Three Months Ended June 30, 2025
(in millions)Commercial SolutionsResearch & Development SolutionsTotal
Revenues:
Americas$825 $1,110 $1,935 
Europe and Africa640 601 1,241 
Asia-Pacific186 655 841 
Total revenues$1,651 $2,366 $4,017 
Six Months Ended June 30, 2026
(in millions)Commercial SolutionsResearch & Development SolutionsTotal
Revenues:
Americas$1,751 $2,272 $4,023 
Europe and Africa1,375 1,389 2,764 
Asia-Pacific421 1,311 1,732 
Total revenues$3,547 $4,972 $8,519 
Six Months Ended June 30, 2025
(in millions)Commercial SolutionsResearch & Development SolutionsTotal
Revenues:
Americas$1,615 $2,127 $3,742 
Europe and Africa1,233 1,232 2,465 
Asia-Pacific375 1,264 1,639 
Total revenues$3,223 $4,623 $7,846 

No individual customer represented 10% or more of consolidated revenues for the three and six months ended June 30, 2026 or 2025.
Transaction Price Allocated to the Remaining Performance Obligations
As of June 30, 2026, approximately $36.4 billion of revenues are expected to be recognized in the future from remaining performance obligations. The Company expects to recognize revenues on approximately 30% of these remaining performance obligations over the next twelve months, on approximately 85% over the next five years, with the balance recognized thereafter. Most of the Company's remaining performance obligations where revenues are expected to be recognized beyond the next twelve months are for service contracts for clinical research in the Company's Research & Development Solutions segment. The customer contract transaction price allocated to the remaining performance obligations differs from backlog in that it does not include wholly unperformed contracts under which the customer has a unilateral right to cancel the arrangement